Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Lapteva N, et al. Among authors: ando j. Cytotherapy. 2012 Oct;14(9):1131-43. doi: 10.3109/14653249.2012.700767. Epub 2012 Aug 17. Cytotherapy. 2012. PMID: 22900959 Free PMC article.
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM. Tanaka M, et al. Among authors: ando j. Clin Cancer Res. 2017 Jul 15;23(14):3499-3509. doi: 10.1158/1078-0432.CCR-16-2138. Epub 2017 Feb 9. Clin Cancer Res. 2017. PMID: 28183713 Free PMC article. Clinical Trial.
Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo.
Ando M, Ando J, Yamazaki S, Ishii M, Sakiyama Y, Harada S, Honda T, Yamaguchi T, Nojima M, Ohshima K, Nakauchi H, Komatsu N. Ando M, et al. Among authors: ando j. Haematologica. 2020 Mar;105(3):796-807. doi: 10.3324/haematol.2019.223511. Epub 2019 Jul 11. Haematologica. 2020. PMID: 31296577 Free PMC article.
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.
Ando M, Nishimura T, Yamazaki S, Yamaguchi T, Kawana-Tachikawa A, Hayama T, Nakauchi Y, Ando J, Ota Y, Takahashi S, Nishimura K, Ohtaka M, Nakanishi M, Miles JJ, Burrows SR, Brenner MK, Nakauchi H. Ando M, et al. Among authors: ando j. Stem Cell Reports. 2015 Oct 13;5(4):597-608. doi: 10.1016/j.stemcr.2015.07.011. Epub 2015 Aug 28. Stem Cell Reports. 2015. PMID: 26321144 Free PMC article.
Primary Lymphoma of the Pericardium.
Kinoshita S, Ando J, Ando M, Komatsu N. Kinoshita S, et al. Among authors: ando j, ando m. Intern Med. 2021 Dec 15;60(24):4005-4006. doi: 10.2169/internalmedicine.7643-21. Epub 2021 Jun 12. Intern Med. 2021. PMID: 34121016 Free PMC article. No abstract available.
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C, Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N. Harada S, et al. Among authors: ando j, ando m. Mol Ther. 2022 Feb 2;30(2):534-549. doi: 10.1016/j.ymthe.2021.10.006. Epub 2021 Oct 8. Mol Ther. 2022. PMID: 34628050 Free PMC article.
524 results